{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:48:20Z","timestamp":1740178100165,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T00:00:00Z","timestamp":1712188800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s41669-024-00482-x","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T18:01:58Z","timestamp":1712253718000},"page":"471-480","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Can Cyprus Afford Luspatercept? A Budget Impact Analysis of the Reimbursement of Luspatercept for the Management of Thalassaemia in Cyprus"],"prefix":"10.1007","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2463-3131","authenticated-orcid":false,"given":"Olga","family":"Pitsillidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4881-720X","authenticated-orcid":false,"given":"Panagiotis","family":"Petrou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6306-3653","authenticated-orcid":false,"given":"M. J.","family":"Postma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,4,4]]},"reference":[{"issue":"5","key":"482_CR1","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3109\/03630269.2013.801851","volume":"37","author":"A Kyrri","year":"2013","unstructured":"Kyrri A, Kalogerou E, Loizidou D, et al. The changing epidemiology of \u03b2-thalassemia in the Greek-cypriot population. Hemoglobin. 2013;37(5):437\u201343.","journal-title":"Hemoglobin"},{"key":"482_CR2","doi-asserted-by":"publisher","unstructured":"Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. Lancet. 2018;391(10116):155\u201367.  https:\/\/doi.org\/10.1016\/S0140-6736(17)31822-6.","DOI":"10.1016\/S0140-6736(17)31822-6"},{"key":"482_CR3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2017.1.265","author":"AT Taher","year":"2017","unstructured":"Taher AT, Saliba AN. Iron overload in thalassemia: different organs at different rates. Hematology. 2017. https:\/\/doi.org\/10.1182\/asheducation-2017.1.265.","journal-title":"Hematology"},{"key":"482_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.12.003","author":"M Betts","year":"2020","unstructured":"Betts M, Flight PA, Clark Paramore L, et al. Systematic literature review of the burden of disease and treatment for transfusion-dependent \u03b2-thalassemia. Clin Therapeutics. 2020. https:\/\/doi.org\/10.1016\/j.clinthera.2019.12.003.","journal-title":"Clin Therapeutics"},{"key":"482_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13512","author":"A Kattamis","year":"2020","unstructured":"Kattamis A, Forni G. Changing patterns in the epidemiology of \u03b2-thalassemia. Eur J Haematol. 2020. https:\/\/doi.org\/10.1111\/ejh.13512.","journal-title":"Eur J Haematol"},{"issue":"3","key":"482_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1076\/jmep.23.3.274.2585","volume":"23","author":"R Hoedemaekers","year":"1998","unstructured":"Hoedemaekers R, Have HT. Geneticization: the Cyprus paradigm. J Med Philos. 1998;23(3):274\u201387.","journal-title":"J Med Philos"},{"key":"482_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(81)91682-2","author":"MA Angastiniotis","year":"1981","unstructured":"Angastiniotis MA, Hadjiminas MG. Prevention of Thalassemia in Cyprus. The Lancet. 1981. https:\/\/doi.org\/10.1016\/S0140-6736(81)91682-2.","journal-title":"The Lancet"},{"key":"482_CR8","doi-asserted-by":"publisher","DOI":"10.17351\/ests2016.48","author":"T Kyriakides","year":"2016","unstructured":"Kyriakides T. Tactics as empirical and conceptual objects: patient activism and the politics of thalassaemia in Cyprus. Enagag Sci Technol Soc. 2016. https:\/\/doi.org\/10.17351\/ests2016.48.","journal-title":"Enagag Sci Technol Soc"},{"key":"482_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/thalassrep12040019","author":"M Angastiniotis","year":"2022","unstructured":"Angastiniotis M, Christou S, Kolnakou A, et al. The outcomes of patients with haemoglobin disorders in Cyprus: a joined report. Thalassemia Reports. 2022. https:\/\/doi.org\/10.3390\/thalassrep12040019.","journal-title":"Thalassemia Reports"},{"key":"482_CR10","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1977116","author":"AT Taher","year":"2021","unstructured":"Taher AT, Bou-Fakhedrin R, Kattamis A, et al. Improving outcomes and quality of life for patients with transfusion-dependent \u03b2-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies. Expert Rev Hematol. 2021. https:\/\/doi.org\/10.1080\/17474086.2021.1977116.","journal-title":"Expert Rev Hematol"},{"key":"482_CR11","unstructured":"Alassaf A, Angastiniotis M and E A et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). 4th ed. Thalassaemia Int Feder; 2021."},{"key":"482_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23732","author":"KM Attie","year":"2014","unstructured":"Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid differentiation, in healthy volunteers. Am J Hematol. 2014. https:\/\/doi.org\/10.1002\/ajh.23732.","journal-title":"Am J Hematol"},{"issue":"13","key":"482_CR13","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1056\/NEJMoa1910182","volume":"382","author":"M Cappellini","year":"2020","unstructured":"Cappellini M, Viprakasit V, Taher A, et al. A phase 3 trial of luspatercept in patients with transfusion-dependent \u03b2-thalassemia. New Eng J Med. 2020;382(13):1219\u201331.","journal-title":"New Eng J Med."},{"key":"482_CR14","doi-asserted-by":"publisher","DOI":"10.51731\/cjht.2021.122","author":"Team, C.R.","year":"2021","unstructured":"Team, C.R. Luspatercept (Reblozyl). Can J Helth Technol. 2021. https:\/\/doi.org\/10.51731\/cjht.2021.122.","journal-title":"Can J Helth Technol"},{"key":"482_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2021.1886108","author":"P Petrou","year":"2021","unstructured":"Petrou P. Budget impact analysis: can we afford the added value? J Med Econ. 2021. https:\/\/doi.org\/10.1080\/13696998.2021.1886108.","journal-title":"J Med Econ"},{"key":"482_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291","author":"SD Sullivan","year":"2014","unstructured":"Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis\u2014principles of good practice: report of the ISPOR 2012 budget impact analysis GoodPractice II Task Force. Value Health. 2014. https:\/\/doi.org\/10.1016\/j.jval.2013.08.2291.","journal-title":"Value Health"},{"key":"482_CR17","doi-asserted-by":"crossref","unstructured":"Delaporta P, Delicou S, Kourakli A et al. Real-world data on the use of Luspatercept in Greek patients with transfusion. HemaSphere. 2021.","DOI":"10.1097\/01.HS9.0000848880.20537.13"},{"issue":"3","key":"482_CR18","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.healthpol.2020.12.018","volume":"125","author":"P Petrou","year":"2021","unstructured":"Petrou P. The 2019 introduction of the new National Healthcare System in Cyprus. Health Policy. 2021;125(3):284\u20139.","journal-title":"Health Policy"},{"key":"482_CR19","doi-asserted-by":"crossref","unstructured":"Pitsillidou O, Petrou P, Postma MJ. Can Cyprus Afford luspatercept? A budget impact analysis of the reimbursement of luspatercept for the management of thalassemia in Cyprus\u2014Supplementary Material. Nicosia. 2024.","DOI":"10.1007\/s41669-024-00482-x"},{"key":"482_CR20","unstructured":"Squibb B-M. European medicines agency. 2020. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/reblozyl-epar-product-information_en.pdf."},{"issue":"4","key":"482_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10198-009-0173-2","volume":"10","author":"B J\u00f6nsson","year":"2009","unstructured":"J\u00f6nsson B. Ten arguments for a societal perspective in the economic evaluation of medical innovations. Eur J Health Econ. 2009;10(4):357\u20139.","journal-title":"Eur J Health Econ"},{"key":"482_CR22","unstructured":"M. o. L. Department of Labour Reations. Available: https:\/\/www.mlsi.gov.cy\/mlsi\/dlr\/dlr.nsf\/page51_en\/page51_en?OpenDocument."},{"key":"482_CR23","unstructured":"H. I. O. Cyprus, \"GESY,\". Available: https:\/\/www.gesy.org.cy\/launchpad.html. [Accessed 22 Feb 2024]."},{"key":"482_CR24","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, M S. Methods for the economic evaluation of health care programmes. York: Oxford; 2015."},{"key":"482_CR25","doi-asserted-by":"publisher","first-page":"4899","DOI":"10.1182\/blood-2022-166881","volume":"140","author":"PL Franco Locatelli","year":"2022","unstructured":"Franco Locatelli PL. Efficacy and safety of a single dose of exagamglogene autotemcel for transfusion-dependent \u03b2-thalassemia. Blood. 2022;140:4899\u2013901. https:\/\/doi.org\/10.1182\/blood-2022-166881.","journal-title":"Blood"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00482-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-024-00482-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-024-00482-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T13:08:17Z","timestamp":1714396097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-024-00482-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,4]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["482"],"URL":"https:\/\/doi.org\/10.1007\/s41669-024-00482-x","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2024,4,4]]},"assertion":[{"value":"3 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The datasets used and\/or analysed during the current study are available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"The parameter values utilized in the model for this BIA are accessible in the published article (as well as its supplementary information files). The model is available from the corresponding author on reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"O. Pitsillidou (PhDc) and Dr P. Petrou are employees of Cyprus Health Insurance Organization (HIO). The views and opinions expressed in this publication are those of the authors. They do not purport to reflect the opinions or views of the HIO. The authors have no relevant affiliations or financial involvement with any organization or entity with financial interest in or financial conflict with the subject matter or materials discussed in this manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}},{"value":"The authors received no financial support for the research, authorship, and\/or publication of this article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"OP and PP conceptualized and designed the model. OP designed and drafted the article. PP and MJP provided study material and revised the initial article. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}